The ACTR1B Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population designed to ablate expression of the ACTR1B gene in the HEK293T host cell line. This loss-of-function model enables systematic investigation of dynactin complex integrity and dynein-dependent intracellular trafficking. By disrupting ACTR1B, researchers can interrogate the functional consequences of impaired dynactin assembly on retrograde axonal transport, mitosis, and nuclear positioning without the confounding effects of off-target mutations inherent to RNAi-based approaches.
The host cell line, HEK293T, is a widely utilized human embryonic kidney epithelial derivative expressing the SV40 large T-antigen. This transformation confers high-level proliferation and permits episomal replication of plasmids containing the SV40 origin of replication, making HEK293T cells a preferred platform for recombinant protein overexpression, lentiviral packaging, and large-scale transient transfections. The cell line??s robust growth profile and amenability to genetic manipulation render it an ideal background for generating polyclonal knockout populations via CRISPR/Cas9.
ACTR1B encodes actin-related protein 1B, a core subunit of the dynactin multiprotein complex that serves as an essential cofactor for cytoplasmic dynein. Dynactin bridges dynein to diverse cargoes??including endosomes, mitochondria, Golgi-derived vesicles, and kinetochores??enabling processive minus-end-directed movement along microtubules. Mechanistically, ACTR1B interacts directly with DCTN1/p150Glued, DCTN2/p50/dynamitin, and the dynein intermediate chain DYNC1I1, facilitating stable complex assembly. Its activity is modulated by upstream regulators such as the dynein adaptors BICD2 and HOOK3, RAB GTPases, and the cell cycle kinase CDK1, while disruption of ACTR1B impairs downstream events like mitotic spindle organization, vesicular trafficking, and lysosomal positioning.
In the HEK293T context, ACTR1B knockout creates a valuable model for dissecting the molecular requirements of dynactin-dependent processes. Loss of ACTR1B disrupts the structural integrity of the dynactin shoulder domain, leading to aberrant dynein processivity and cargo tethering. Researchers can utilize this system to characterize phenotypes such as Golgi apparatus dispersal, delayed mitotic progression, and impaired mitochondrial transport using immunofluorescence microscopy and live-cell imaging. Co-immunoprecipitation assays enable assessment of residual dynactin subcomplex formation, while western blotting confirms ACTR1B ablation and monitors compensatory changes in related subunits like ACTR1A.
This polyclonal knockout population is particularly suited for applications in neurodegenerative disease research, given the established links between dynactin dysfunction and disorders such as Perry syndrome, distal hereditary motor neuropathy, and amyotrophic lateral sclerosis. High-throughput screening campaigns can identify small molecules that restore dynein-dynactin function or modulate interacting factors like BICD2 and HOOK3. Additional applications include cell cycle analysis by flow cytometry, migration assays to assess nuclear positioning, and validation of putative dynein cargo adaptors. The product serves as a defined, genetically tractable platform for exploring the fundamental biology of retrograde transport. For additional product specifications or customization inquiries, please contact Ascent Research.
